U.S. Markets close in 2 hrs 58 mins

Pieris Pharmaceuticals, Inc. (PIRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.3000+0.1400 (+4.43%)
As of 1:01PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1600
Open3.2400
Bid3.3000 x 1100
Ask3.3100 x 1200
Day's Range3.1804 - 3.4510
52 Week Range1.6000 - 5.9700
Volume996,178
Avg. Volume490,023
Market Cap172.915M
Beta (5Y Monthly)1.35
PE Ratio (TTM)N/A
EPS (TTM)-0.4170
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Recap: Pieris Pharmaceuticals Q2 Earnings

    Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) rose 8% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 62.50% year over year to ($0.09), which beat the estimate of ($0.17).Revenue of $11,246,000 higher by 110.92% year over year, which beat the estimate of $7,760,000.Guidance Earnings guidance hasn't been issued by the company for now.Pieris Pharmaceuticals hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 10, 2020View more earnings on PIRSTime: 08:00 AMET Webcast URL: https://www.pieris.com/news-and-events/upcoming-eventsPrice Action Company's 52-week high was at $5.9752-week low: $1.60Price action over last quarter: Up 7.05%Company Overview Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.See more from Benzinga * Earnings Scheduled For August 10, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Pieris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

    "We look forward to beginning the phase 2 trials of our lead clinical programs, PRS-343 and PRS-060, later this year.